BioLife Solutions, Inc. (BLFS)

NASDAQ: BLFS · IEX Real-Time Price · USD
14.56
-0.10 (-0.68%)
Jun 29, 2022 4:00 PM EDT - Market closed

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.

The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.

The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services.

It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions, Inc.
BioLife Solutions Logo
Country United States
Founded 1987
IPO Date Nov 22, 1989
Industry Health Care Equipment & Supplies
Sector Health Care
Employees 432
CEO Michael Rice

Contact Details

Address:
3303 Monte Villa Pkwy Ste 310
Bothell, Washington 98021-6200
United States
Phone 425 402 1400
Website biolifesolutions.com

Stock Details

Ticker Symbol BLFS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000834365
CUSIP Number 09062W105
ISIN Number US09062W2044
Employer ID 94-3076866
SIC Code 3845

Key Executives

Name Position
Michael P. Rice Chairman and Chief Executive Officer
Roderick de Greef President and Chief Operating Officer
Troy Wichterman Chief Financial Officer
Dr. Aby J. Mathew Chairman of Scientific Advisory Board, Executive Vice President and Chief Scientific Officer
Marcus Schulz Chief Revenue Officer
Todd Berard Chief Marketing Officer
Sarah Aebersold J.D. Vice President of Global Human Resources
Karen Foster Chief Quality Officer

Latest SEC Filings

Date Type Title
Jun 22, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 8-K Current report
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities